Table 1.
Compound | Heterologous host | Substrate provision pathway | Final titer(s) (intermediate or final compound)b | Step to enable or overproduce product | Reference |
---|---|---|---|---|---|
Paclitaxel | E. coli | MEP | 1.3 mg/liter (taxadiene) | Overexpression of dxs and idi | 26 |
300 mg/liter (taxadiene), 58 mg/liter (taxadiene-5α-ol) | Overexpression and variation of copy number and promoter of dxs, idi, ispD, and ispF | 2 | |||
S. cerevisiae | MVA | 1.0 mg/liter (taxadiene), 0.025 mg/liter (taxadiene-5α-ol) | None | 15 | |
8.7 mg/liter (taxadiene) | Overexpression of a truncated HMG-CoA reductase; reduction of competing steroid pathway | 16 | |||
Artemisinin | E. coli | MVA | 155 mg/liter (amorphadiene; initial titer) | Introduction and overexpression of MVA pathway; foreign gene codon optimization; promoter variation; plasmid copy number variation; specific overexpression of mevalonate kinase | 39 |
1,084 mg/literc (amorphadiene; optimized titer) | 4 | ||||
105 mg/liter (artemisinic acid) | Overexpression of MVA pathway; foreign gene codon optimization; promoter variation | 10 | |||
S. cerevisiae | MVA | 0.6 mg/liter | None | 38 | |
153 mg/liter (amorphadiene), 32 mg/liter (artemisinic acid) | Overexpression of a truncated HMG-CoA reductase; reduction of competing steroid pathway | 52 | |||
Carotenoids | E. coli | MEP | 6 mg/g DCW (β-carotene) | Overexpression of dxs, ispD, ispF, ispB, and idi | 72 |
MVA | 22 mg/g DCW (lycopene) | Overexpression of mvaK1 (mvk), mvaK2 (pmk), mvaD (pmd), and idi | 71 | ||
12.5 mg/g DCW (lycopene) | Overexpression of MVA pathway with acetoacetyl-CoA ligase introduced | 21 | |||
S. cerevisiae | MVA | 0.113 mg/g DCW (lycopene) | None | 70 | |
5.9 mg/g DCW (β-carotene) | Overexpression of a truncated HMG-CoA reductase and endogenous geranylgeranyl diphosphate synthase | 64 |
Examples are not comprehensive.
DCW, dry cell weight.
Estimated based upon an optical density at 600 nm (OD600) of 3.7 (39); the actual value reported is 293 mg/liter/unit of OD600.